Net‐clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more

Samama, 1999, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group, N Engl J Med, 341, 793, 10.1056/NEJM199909093411103 Leizorovicz, 2004, Randomized, placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients, Circulation, 110, 874, 10.1161/01.CIR.0000138928.83266.24 Cohen, 2006, Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial, BMJ, 332, 325, 10.1136/bmj.38733.466748.7C Dentali, 2007, Meta‐analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients, Ann Intern Med, 20, 278, 10.7326/0003-4819-146-4-200702200-00007 Hull, 2010, Ann Intern Med, 153, 8, 10.7326/0003-4819-153-1-201007060-00004 Goldhaber, 2011, ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients, N Engl J Med, 365, 2167, 10.1056/NEJMoa1110899 Cohen, 2013, Rivaroxaban for thromboprophylaxis in acutely ill medical patients, N Engl J Med, 368, 513, 10.1056/NEJMoa1111096 Violi, 2013, Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials, Thromb Haemost, 109, 589, 10.1160/TH12-11-0860 Kahn, 2012, Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence‐based clinical practice guidelines, Chest, 141, e195S, 10.1378/chest.11-2296 Barbar, 2010, A risk assessment model for the identification of hospitalized medical patients a risk for venous thromboembolism: the Padua Prediction Score, J Thromb Haemost, 8, 2450, 10.1111/j.1538-7836.2010.04044.x Mahan, 2014, External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely‐ill medical patient (VTE‐VALOURR), Thromb Haemost, 112, 692, 10.1160/TH14-03-0239 Decousus, 2011, Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators, Chest, 139, 69, 10.1378/chest.09-3081 Weitz, 2012, New antithrombotic drugs. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines, Chest, 141, e120S, 10.1378/chest.11-2294 Cohen, 2014, The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study, Am Heart J, 167, 335, 10.1016/j.ahj.2013.11.006 Cohen, 2016, Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients, N Engl J Med, 375, 534, 10.1056/NEJMoa1601747 Schulman, 2005, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Kucher, 2005, Efficacy and safety of fixed low‐dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients, Arch Intern Med, 165, 341, 10.1001/archinte.165.3.341 Yusen, 2013, Impact of age on the efficacy and safety of extended‐duration thromboprophylaxis in medical patients, Thromb Haemost, 110, 1152, 10.1160/TH13-02-0170 Gibson, 2017, The safety and efficacy of full‐ versus reduced‐dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended‐Duration Betrixaban (APEX) trial, Am Heart J, 185, 93, 10.1016/j.ahj.2016.12.004 Ageno, 2012, Safety and efficacy of low‐dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study, J Thromb Haemost, 10, 2291, 10.1111/j.1538-7836.2012.04908.x